Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated deaths worldwide. Treatment with immune checkpoint antibodies has shown promise in advanced HCC, but the response is only 15-20%. We discovered a potential target for the treatment of HCC, the cholecystokinin-B receptor (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2023-02, Vol.24 (4), p.3625
Hauptverfasser:	Shivapurkar, Narayan, Gay, Martha D, He, Aiwu Ruth, Chen, Wenqiang, Golnazar, Shermineh, Cao, Hong, Duka, Tetyana, Kallakury, Bhaskar, Vasudevan, Sona, Smith, Jill P
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antimitotic agents Antineoplastic agents Apoptosis Cancer therapies Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - metabolism CD8 antigen Cell death Cholecystokinin Cholecystokinin receptors Drug therapy FDA approval Fibrosis Gene expression Genes Health aspects Hepatocellular carcinoma Hepatoma Immune checkpoint Immune Checkpoint Inhibitors - immunology Immunotherapy Kinases Liver Liver cancer Liver Neoplasms - immunology Liver Neoplasms - metabolism Lymphocytes Lymphocytes T Mesenchyme Mice Pancreatic cancer PD-1 protein Peptides Proglumide - pharmacology Receptors, Cholecystokinin - antagonists & inhibitors RNA RNA sequencing Survival T cells Tumor microenvironment Tumorigenesis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!